Biogen’s executive vice president of global commercial operations has left the company and a search has been initiated for his replacement.
During the interim period, his responsibilities will be assumed by John Cox who is executive VP of pharmaceutical operations and technology.
George Scangos, CEO at Biogen, said: “Tony has made significant contributions to Biogen. He led the successful introduction of five important new products and helped serve patients around the world with our life-transforming therapies. All of us wish Tony the best in his future endeavours.”
Kingsley joined Biogen in 2010 as senior VP and during his tenure Biogen introduced five new therapies including successfully launching Tecfidera (dimethyl fumarate) – the most prescribed oral treatment for multiple sclerosis.
Scangos added: “We are pleased that John will lead our commercial operations on an interim basis. His 12 years at Biogen and in-depth knowledge our pharmaceutical and commercial operations give us great confidence that we will continue to execute on the commercial opportunities at-hand as we search for a permanent leader.”